# Federal Survey Finds Youth Cannabis Use Declined in 2025 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/nsduh-2025-youth-cannabis-use/ > **Published:** 2026-07-27T23:11:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:20-04:00 > **Clinical Summary:** NSDUH 2025 youth cannabis use declined while adult trends differed. CED explains the federal findings, clinical relevance, and limits. --- CED Clinical Relevance #88 National cannabis public-health surveillance SAMHSA’s newly released 2025 national survey provides current, nationally representative estimates for adolescent, young-adult, and adult [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). The findings matter for family counseling and policy, but the observational trend data cannot establish why use changed. Clinical Insight | CED Clinic The 2025 NSDUH offers a useful population-level signal, not a prediction for any individual adolescent. Past-month [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) declined among adolescents and young adults between 2021 and 2025, while use increased among adults age 26 and older. That pattern should discourage simplistic claims that youth use is inevitably rising, but it does not prove that legalization caused the decline. Families and clinicians still need to ask about product type, THC concentration, route, frequency, co-use, driving, school function, mood, sleep, and signs of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/). A lower national prevalence does not make early or frequent use harmless for the young people who do use cannabis. NSDUH 2025Youth [Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/)Public HealthFamiliesFederal Data Audience Patients, families, clinicians, educators, public-health readers, and cannabis policy readers. Primary Topic What the 2025 National Survey on Drug Use and Health shows, and does not show, about cannabis use across age groups. Source [Read the 2025 SAMHSA report](https://www.samhsa.gov/data/report/2025-nsduh-annual-national-report) New federal survey data show lower adolescent and young-adult cannabis use from 2021 to 2025, alongside higher use among older adults. The trend is important, but it does not identify a single cause. What This Study Teaches Us SAMHSA estimates that 8.7 percent of adolescents ages 12 to 17 used cannabis in the past year in 2025. Past-month use among adolescents fell from 6.1 percent in 2021 to 5.0 percent in 2025, while past-month use increased among adults age 26 and older. Why This Matters National trends can improve prevention, screening, and counseling priorities. They can also be misused when a descriptive survey is presented as proof that one policy caused the change. Study Snapshot Source Substance Abuse and Mental Health Services Administration Survey 2025 National Survey on Drug Use and Health Population U.S. civilian, noninstitutionalized population age 12 or older Adolescent result 8.7 percent reported past-year cannabis use Past-month trend Adolescent use fell from 6.1 percent in 2021 to 5.0 percent in 2025 Young adults Past-month cannabis use also declined from 2021 to 2025 Adults 26 and older Past-month cannabis use increased from 2021 to 2025 Evidence type National self-report surveillance survey Important boundary The survey does not establish that legalization caused the age-specific trends Clinical Bottom Line Youth cannabis use declined in this federal survey period, but prevention and clinical screening still matter, and the data do not prove why the decline occurred. Opening News Brief SAMHSA released the 2025 National Survey on Drug Use and Health on July 27, 2026. The report estimates that 8.7 percent of adolescents ages 12 to 17 used cannabis in the past year, and 5.0 percent used it in the past month. The federal report found that past-month cannabis use declined among adolescents and young adults from 2021 to 2025, while it increased among adults age 26 and older. [Read the primary federal report](https://www.samhsa.gov/data/report/2025-nsduh-annual-national-report). For Patients and Families A favorable national trend does not tell a family whether a particular teenager is using cannabis or experiencing harm. Calm, specific conversations about frequency, product strength, vaping, edibles, driving, sleep, school, anxiety, and other substance use remain more useful than assumptions. Seek clinical help when use is frequent, hard to control, linked to impairment or safety problems, or accompanied by withdrawal, mood changes, declining function, or use despite harm. For Clinicians Use the national estimate as context, not as a substitute for screening. Ask neutrally about route, THC concentration, frequency, reasons for use, co-use, driving, pregnancy, medications, mental health, and functional consequences. Avoid interpreting a lower population prevalence as lower risk for adolescents with early, frequent, high-potency, or polysubstance exposure. How This Fits the Bigger Picture The report shows divergent age patterns. Adolescent and young-adult past-month use moved downward from 2021, while use among adults age 26 and older moved upward. That divergence supports age-specific prevention and counseling. It also argues against treating national cannabis use as a single trend shared by every population. What This Does Not Show NSDUH is not a randomized policy experiment. It cannot show that adult-use legalization, retail safeguards, education campaigns, social changes, or any other single factor caused the decline among young people. The survey also does not measure the safety of a specific product, dose, route, or pattern of use, and self-report can be affected by recall and willingness to disclose. Key Clinical Caveats Cannabis products differ markedly in THC concentration, CBD content, formulation, and route. Past-year use combines very different exposure patterns, from isolated use to frequent high-potency use. Risk assessment should consider age at initiation, frequency, intoxication, driving, pregnancy, psychiatric symptoms, other substances, medication interactions, and evidence of impaired control or function. Where It Deserves Skepticism Advocacy organizations may cite the decline as proof that legalization protects youth, while opponents may focus only on higher adult use. Neither conclusion follows automatically from descriptive national trends. The most defensible reading is narrower: reported youth use declined during the measured period, adult patterns differed, and causal policy claims require separate analysis. Policy and Public Health Angle Policymakers should track prevalence together with frequency, product potency, route, [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), poisonings, impaired driving, school function, treatment need, and disparities. A single prevalence number cannot describe the full burden of harm. Prevention should remain accurate and credible. Young people need clear information about impairment and risk without exaggerated claims that conflict with observable national trends. How Strong Is This Evidence? Strong for national self-reported prevalence estimates and age-specific trends within the comparable 2021 to 2025 NSDUH period. Limited for causal conclusions about legalization or other policies, and limited for characterizing product potency or individual risk. Where This Paper Deserves Skepticism The survey is nationally representative but observational and self-reported. Its age-group trends should not be converted into causal claims or used to minimize risks among adolescents who use frequently or experience impairment. What This Paper Does Not Show The report does not prove that legalization reduced youth use, establish that adolescent cannabis exposure is safe, identify the effect of a specific [state policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/), or replace individual clinical assessment. How This Fits With the Broader Clinical Conversation Age-specific patterns matter more than one combined national cannabis-use number. Prevalence, frequency, potency, impairment, and [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) are different public-health measures. Dr. Caplan’s Take *This is encouraging news, but it should make our counseling more precise, not more complacent. The national trend suggests that rising adult access has not been accompanied by an inevitable rise in reported adolescent use during this period.* *The clinical task is still individual. A teenager using high-potency products frequently, driving after use, struggling at school, or using cannabis to manage untreated anxiety needs attention even when the national average is moving in a favorable direction.* What a Careful Reader Should Take Away Youth cannabis use declined in the latest federal survey, but the survey does not prove why. Keep prevention, honest screening, and individualized risk assessment in place. Evidence Interpretation Guide Table of Contents - [How to Read the 2025 NSDUH Cannabis Findings](#How_to_Read_the_2025_NSDUH_Cannabis_Findings)[Four distinctions that matter](#Four_distinctions_that_matter) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Lower Use Is Encouraging](#Lower_Use_Is_Encouraging) - [Keep Screening Specific](#Keep_Screening_Specific) - [Talk Without Hype](#Talk_Without_Hype) - [Teach Product Differences](#Teach_Product_Differences) - [Do Not Claim Causation](#Do_Not_Claim_Causation) - [Resist Selective Framing](#Resist_Selective_Framing) - [Look Beyond Prevalence](#Look_Beyond_Prevalence) - [Measure What Matters](#Measure_What_Matters) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read the 2025 NSDUH Cannabis Findings This is national surveillance, not a policy experiment. The age-specific trends move in different directions. ### Four distinctions that matter **Past-year versus past-month use**These measures describe different recency windows and should not be treated as interchangeable. **Prevalence versus intensity**Any use does not reveal frequency, dose, potency, route, or functional impact. **Trend versus cause**A change over time does not identify which policies or social factors produced it. **Population versus patient**National estimates provide context but cannot determine one person’s risk or care needs. The Public Health Question Are fewer young people using cannabis, and are those who use experiencing less harm? The Family Question What are the product, frequency, context, and functional effects for this young person? The Bottom Line Read prevalence alongside intensity, impairment, product characteristics, and age-specific context. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview The survey has different implications for adolescents, families, clinicians, educators, policymakers, skeptical readers, safety planning, and public-health surveillance. #### Lower Use Is Encouraging National youth use declined. Individual harms still require attention. Lens takeaway A population trend is not personal clearance. #### Keep Screening Specific Ask about route and frequency. Assess impairment and mental health. Lens takeaway Context matters more than a yes-or-no question. #### Talk Without Hype Use calm, accurate language. Focus on safety and function. Lens takeaway Credibility supports honest disclosure. #### Teach Product Differences THC strength and route vary. Edibles and vapes need specific discussion. Lens takeaway Cannabis is not one uniform exposure. #### Do Not Claim Causation Track policy and outcomes separately. Compare states with careful methods. Lens takeaway Trend data cannot identify one cause. #### Resist Selective Framing Youth and adult trends differ. Advocacy claims need stronger designs. Lens takeaway Read the complete age pattern. #### Look Beyond Prevalence Monitor driving and poisonings. Track frequent and high-potency use. Lens takeaway Fewer users does not describe every harm. #### Measure What Matters Follow disorder and treatment need. Examine disparities and access to care. Lens takeaway Surveillance should connect use with outcomes. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Federal+Survey+Finds+Youth+Cannabis+Use+Declined+in+2025&url=https%3A%2F%2Fcedclinic.com%2Fnsduh-2025-youth-cannabis-use%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fnsduh-2025-youth-cannabis-use%2F) [BlueSky](https://bsky.app/intent/compose?text=Federal+Survey+Finds+Youth+Cannabis+Use+Declined+in+2025%20https%3A%2F%2Fcedclinic.com%2Fnsduh-2025-youth-cannabis-use%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Key Substance Use and Mental Health Indicators in the United States: Results from the 2025 National Survey on Drug Use and Health](https://www.samhsa.gov/data/report/2025-nsduh-annual-national-report) Related Reading at CED Clinic Continue exploring the evidence [Minnesota Teen Cannabis Use Fell, but Major Social Disparities Persist](https://cedclinic.com/minnesota-adolescent-cannabis-use-disparities-2026/) A state-level adolescent survey showing why subgroup disparities can remain even when overall use declines. [Compare the Minnesota data](https://cedclinic.com/minnesota-adolescent-cannabis-use-disparities-2026/) [Understanding New York’s Cannabis Honestly Campaign for Families and Clinicians](https://cedclinic.com/new-york-cannabis-honestly-campaign-education/) A practical look at youth cannabis education, credible risk communication, and family conversations. [Read the prevention context](https://cedclinic.com/new-york-cannabis-honestly-campaign-education/) [U.S. Child Cannabis Exposures Through 2024](https://cedclinic.com/us-child-cannabis-exposures-through-2024-poison-center-study/) National poison-center evidence showing why prevalence trends and pediatric exposure harms are different measures. [Review the exposure evidence](https://cedclinic.com/us-child-cannabis-exposures-through-2024-poison-center-study/) ## Frequently Asked Questions What did the 2025 NSDUH report about [adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/)? SAMHSA estimated that 8.7 percent of adolescents ages 12 to 17 used cannabis in the past year and 5.0 percent used it in the past month in 2025. Did adolescent past-month cannabis use decline? Yes. The estimate declined from 6.1 percent in 2021 to 5.0 percent in 2025 within the comparable survey period. What happened among young adults? Past-month cannabis use among adults ages 18 to 25 also declined from 2021 to 2025. What happened among adults age 26 and older? Past-month cannabis use increased among adults age 26 and older from 2021 to 2025. Does the survey prove legalization reduced youth cannabis use? No. The survey describes trends but cannot establish that legalization or any single policy caused them. Is NSDUH nationally representative? It is designed to represent the U.S. civilian, noninstitutionalized population age 12 or older. What is a major limitation of the survey? The estimates rely on self-report, and broad use measures do not fully describe dose, potency, route, frequency, or functional harm. Does lower national youth use mean cannabis is safe for adolescents? No. A lower prevalence estimate does not eliminate developmental, psychiatric, impairment, poisoning, or cannabis use disorder concerns. What should clinicians ask adolescents about? Ask neutrally about product type, THC concentration, route, frequency, reasons for use, co-use, driving, mood, sleep, school, and loss of control. What should public-health agencies track next? Track prevalence together with frequency, potency, route, disorder, poisonings, driving, treatment need, functional outcomes, and disparities. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).